Retrospect and reflection on the construction of large-scale technology platform of the State Key Laboratory of Natural and Biomimetic Drugs in 2018-2020

doi:10.5246/jcps.2019.12.083

Abstract

Abstract:

The State Key Laboratory of Natural and Biomimetic Drugs was approved for a funding of nearly 100 million yuan specifically aimed at the purchase and maintenance of equipment and instruments from 2018 to 2020, which is a record high. The Laboratory focuses on two major directions of scientific research, the “basic scientific problems of drug resistance of complex components of natural products” and the “key biomimetic scientific problems of endogenous substances therapeutic functions”. The selection of scientific instruments and equipment, trial production, upgrading, as well as high level of technical and managementpersonnel allocation and other aspects are critical to meet the development needs of the Key Laboratory and to maintain the advantages and leading role in these two major directions of scientific research.

Key words: Instrument platform construction, Optimization of resource allocation, Scientific research service

CLC Number:

Supporting:

Shuxiang Song. Retrospect and reflection on the construction of large-scale technology platform of the State Key Laboratory of Natural and Biomimetic Drugs in 2018-2020[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(12): 878-884.

References

[1] Zhou, D.M. Preface: Special issue on drug innovation driven by the integration of chemical biology of State Key Labortory of Natural and Biomimetic Drugs. Sci. Sin. Chim. 2018, 48, 1291-1292.

[2] Si, L.L.; Xu, H.; Zhou, X.Y.; Zhang, Z.W.; Tian, Z.Y.; Wang, Y.; Zhang, B.; Niu, Z.L.; Yao, T.; Li, S.; Zhang, C.L; Fu, G.; Xiao, S.L.; Xia, Q.; Zhang, L.H.; Zhou, D.M. Generation of Influenza A Viruses as Live but Replication-Incompetent Virus Vaccines. Science. 2016, 354, 1170-1173.

[3] Liu, J.Z; Qiu, X.; Huang, X.Q; Luo, X.; Zhang, C.; Wei, J.L.; Pan, J.; Liang, Y.J.; Zhu, Y.C; Qin, Q.X.; Song, S.; Jiao, N. From alkylarenes to anilines via site-directed carbon-carbon amination. Nat. Chem. 2019, 11, 71-77.

[4] Si, L.L.; Meng, K.; Tian, Z.Y.; Sun, J.Q.; Li, H.Q.; Zhang, Z.W.; Soloveva, V.; Li, H.W.; Fu, G.; Xia, Q.; Xiao, S.L.; Zhang, L.H.; Zhou, D.M. Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes. Sci. Adv. 2018, 4.

[5] Tang, H.T.; Dai, Z.; Qin, X.W.; Cai, W.K; Hu, L.M; Huang, Y.J.; Cao, W.B.; Yang, F.; Wang, C.; Liu, T. Proteomic Identification of Protein Tyrosine Phosphatase and Substrate Interactions in Living Mammalian Cells by Genetic Encoding of Irreversible Enzyme Inhibitors. JACS. 2018, 140, 13253-13259.

[6] Li, L.; Yuan, K.; Jia, Q.L.; Jia, Y.X. Eight-Step Total Synthesis of Phalarine by Bioinspired Oxidative Coupling of Indole and Phenol. Angew. Chem-Int. Ed. 2019, 58, 6074-6078.

[7] Liao, L.X.; Song, X.M.; Wang, L.C.; Lv, H.N.; Chen, J.F.; Liu, D.; Fu, G.; Zhao, M.B.; Jiang, Y.; Zeng, K.W.; Tu, P.F. Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy. PNAS. 2017, 114, E5986-E5994.

[8] Wu, Y.; Xiong, D.C.; Chen, S.C.; Wang, Y.S.; Ye, X.S. Total synthesis of mycobacterial arabinogalactan containing 92 monosaccharide units. Nat. Commun. 2017, 8.

[9] Sun, L.; Wu, X.; Xiong, D.C.; Ye, X.S. Stereoselective Koenigs-Knorr Glycosylation Catalyzed by Urea. Angew. Chem-Int. Ed. 2016, 55, 8041-8044.

[10] Xiao, A.; Zheng, X.J.; Song, C.; Gui, Y.; Huo, C.X.; Ye, X.S. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines. Org. & Biomol. Chem. 2016, 14, 7226-7237.

[11] Liu, Y.; Lai, S.; Ma, W.; Ke, W.; Zhang, C.; Liu, S.; Zhang, Y.; Pei, F.; Li, S.; Yi, M.; Shu, Y.; Shang, Y.; Liang, J.; Huang, Z. CDYL suppresses epileptogenesis in mice through repression of axonal Nav1.6 sodium channel expression. Nat. Commun. 2017, 8.

[12] Lin, Z.H.; Liu, J.M.; Ding, H.D.; Xu, F.; Liu, H.L. Structural basis of SALM5-induced PTP delta dimerization for synaptic differentiation. Nat. Commun. 2018, 9.

[1]	Shen Lin, Xin Rao, Yiyuan Li, Xiuhua Weng, Changlian Wang. Cost-effectiveness analysis of second-line chemotherapy strategies for patients with advanced non-squamous non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 542-553.
[2]	Chengxin Xie, Wei Wang, Ge Huang, Xin Jin, Chenglong Wang, Dong Yin. Pharmacist-led interventions to reduce inappropriate drug use in the orthopaedics department in China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(6): 375-382.
[3]	Yuyao Nie, He Wang, Linguang Zhou, Luwen Shi, Bin Jiang. Pharmacists’ perceptions of generic drugs in China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 364-368.
[4]	Shuxiang Song. Discussion of the process control of large-scale instruments and equipment procurement in State Key Laboratory [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(3): 214-219.
[5]	Zhifeng Nie, Chunxia Man, Xin Yi, Yi Liu, Zhigang Guo, Xiaodong Guan, Luwen Shi. Impact of the zero-markup drug policy on volume of medical service: based on 57 county hospitals of China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(3): 220-226.
[6]	Ruojing Zhou, Bin Jiang. Effects of drug purchasing under joint price caps policy in Fujian Province, China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(2): 139-152.
[7]	Ruirui Zhou, Liqun Wang, Tong Sun, Ziyang Wu, Xiaohui Xie. The efficacy and safety of three types of combination therapies in patients with moderate to very severe COPD: a systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(7): 502-518.
[8]	Zhuangfei Wang, Xiaodong Guan, Yue Zhou, Sheng Han, Peng Yao, Luwen Shi. Prevalence and influence factors of self-medication in Chinese middle-aged and elderly people: evidence from 2011, 2013 and 2015 CHARLS panel data [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 430-438.
[9]	Dongsheng Yang, Lingyun Ma, Jianzhao Niu, Mingdi Xu. Brief introduction for application of USA authorized generic drugs [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 439-445.
[10]	Zhiyong Dong, Xiantu Qiu, Stacy A. Kujawa, S.M. Shariful Islam, Jie Zhang. Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 264-275.
[11]	Min Chen, Feng Jiang, Ming Zheng, Limei Yang, Hongjin Gao. Design and implementation of mobile APP for medication guidance related to pharmacogenomic based on APICloud platform [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 276-283.
[12]	Qi Zhang, Bo Zhang, Nengming Lin. Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 195-202.
[13]	Dongsheng Yang, Lingyun Ma, Jianzhao Niu, Mingdi Xu. Brief introduction for application of the USA national drug code [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 203-208.
[14]	Xinpu Lu, Zhigang Guo, Mengyuan Fu, Haishaerjiang Wushouer, Luwen Shi, Xiaodong Guan. The impacts of national essential medicine policies on the rational use of medicines in China: A cross-sectional study in primary health care institution [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(1): 49-55.
[15]	Chao Zhang, Ruohan Xie, Chuhui Wang, Chenchen Xi, Mengjia Ge. Dose optimization of piperacillin/tazobactam in patients with renal dysfunction based on population pharmacokinetic and pharmacodynamic simulations [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(12): 824-831.